Purinergic calcium signaling drives drug tolerance through ERK reactivation in BRAF-mutant melanoma

We report a previously unrecognized signaling mechanism underlying drug tolerance in BRAF-mutant melanoma treated with BRAF inhibitors. Its key feature is sustained intracellular Ca(2+) signaling initiated by purinergic ligand-gated cation channels, P2X receptors. Src family kinases act as mediators...

Descripción completa

Detalles Bibliográficos
Autores principales: Stauffer, Philip E., Brinkley, Jordon, Jacobson, David, Quaranta, Vito, Tyson, Darren R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635130/
https://www.ncbi.nlm.nih.gov/pubmed/37961267
http://dx.doi.org/10.1101/2023.11.03.565532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635130/
https://www.ncbi.nlm.nih.gov/pubmed/37961267
http://dx.doi.org/10.1101/2023.11.03.565532

Ejemplares similares